tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

LNTH Stock Latest News

Lantheus Announces Two Key Executive Promotions
Press ReleasesLantheus Announces Two Key Executive Promotions
7d ago
LNTH
Lantheus appoints Paul Blanchfield as president, Dan Niedzwiecki as CAO
The FlyLantheus appoints Paul Blanchfield as president, Dan Niedzwiecki as CAO
7d ago
LNTH
Lantheus initiated with an Outperform at JMP Securities
The FlyLantheus initiated with an Outperform at JMP Securities
16d ago
LNTH
Lantheus management to meet with Truist
The FlyLantheus management to meet with Truist
24d ago
LNTH
Lantheus management to meet with Truist
The FlyLantheus management to meet with Truist
25d ago
LNTH
Lantheus price target raised to $115 from $105 at Mizuho
The FlyLantheus price target raised to $115 from $105 at Mizuho
28d ago
LNTH
Lantheus Blasts Up as Earnings Impress
Market NewsLantheus Blasts Up as Earnings Impress
29d ago
LNTH
Lantheus sees FY23 adjusted EPS $4.95 – $5.10, consensus $4.21
The FlyLantheus sees FY23 adjusted EPS $4.95 – $5.10, consensus $4.21
29d ago
LNTH
Lantheus sees Q1 adjusted EPS $1.28-$1.32, consensus $1.06
The FlyLantheus sees Q1 adjusted EPS $1.28-$1.32, consensus $1.06
29d ago
LNTH
Lantheus reports Q4 adjusted EPS $1.37, consensus 96c
The FlyLantheus reports Q4 adjusted EPS $1.37, consensus 96c
29d ago
LNTH
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
Press ReleasesLantheus Reports Fourth Quarter and Full Year 2022 Financial Results
29d ago
LNTH
Lantheus presents data on piflufolastat F 18 at 2023 ASCO symposium
The FlyLantheus presents data on piflufolastat F 18 at 2023 ASCO symposium
1M ago
LNTH
Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
Press ReleasesLantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
1M ago
LNTH
Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time
Press ReleasesLantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time
1M ago
LNTH
Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Press ReleasesLantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
1M ago
LNTH
Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease
Press ReleasesLantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease
2M ago
LNTH
Point Biopharma completes randomization in PNT2002’s Phase 3 Splash trial
The FlyPoint Biopharma completes randomization in PNT2002’s Phase 3 Splash trial
2M ago
PNT
LNTH
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
Press ReleasesLantheus to Present at the J.P. Morgan 2023 Healthcare Conference
3M ago
LNTH
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
Press ReleasesLantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
3M ago
LNTH
Lantheus announces closing of strategic collab, license agreements with POINT
The FlyLantheus announces closing of strategic collab, license agreements with POINT
3M ago
PNT
LNTH
Point Biopharma announces closing of agreements with Lantheus
The FlyPoint Biopharma announces closing of agreements with Lantheus
3M ago
PNT
LNTH
Lantheus grants rights for use of microbubbles to SonoThera
The FlyLantheus grants rights for use of microbubbles to SonoThera
3M ago
LNTH
Lantheus announces pricing of offering of $500M convertible senior notes
The FlyLantheus announces pricing of offering of $500M convertible senior notes
4M ago
LNTH
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
Press ReleasesLantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
4M ago
LNTH
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
Press ReleasesLantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
4M ago
LNTH
Lantheus announces proposed offering of $500M convertible senior notes
The FlyLantheus announces proposed offering of $500M convertible senior notes
4M ago
LNTH
Lantheus appoints Amanda Morgan SVP, commercial
The FlyLantheus appoints Amanda Morgan SVP, commercial
4M ago
ACAD
LNTH
Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
Press ReleasesLantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
4M ago
LNTH
Lantheus announces China NMPA approval of DEFINITY
The FlyLantheus announces China NMPA approval of DEFINITY
4M ago
LNTH
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.